20/20 Biolabs Inc. (AIDX)
NASDAQ: AIDXHealth CarePrecision InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
AIDX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.20M
- EPS (TTM)
- -$0.75
- Dividend yield
- None
- 52-week range
- 0.1556 – 50.00
- Day range
- 0.1556 – 0.1803
- Volume / Avg
- 301.48K / 139.24K
- Beta
- —
- Shares outstanding
- 13.99M
52-week range
AIDX stock today
On Nov 20, AIDX ended the session at $0.1571, shedding $0.0245 (13.49%), versus the S&P 500's 3.70% decline. Volume was 2.2x the average at 301.48K shares, a sign of unusually heavy trading. At this level, AIDX sits near the bottom of its 52-week range of $0.1556 to $50.00: 99.7% below the high and 1.0% above the low.
20/20 Biolabs has posted a net loss over the last twelve months (EPS of -$0.75), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About 20/20 Biolabs
Company profile20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers.
- Sector
- Health Care
- Industry
- Precision Instruments
- CEO
- Mr. Jonathan Cohen
- Headquarters
- Gaithersburg, MD
- Employees
- 4
- Website
- 2020biolabs.com
Financial highlights
Full financialsIn fiscal 2025, 20/20 Biolabs generated $2.0 million in revenue, up 16.7% from fiscal 2024. 20/20 Biolabs reported a net loss of $3.7 million, compared with a loss of $5.6 million a year earlier. Gross margin was 29.6% (up from 20.6%) and operating margin -162.9%.
| Fiscal year | FY 2025 | FY 2024 |
|---|---|---|
| Revenue | $2.05M | $1.75M |
| Growth | +16.71% | — |
| Net income | $-3.74M | $-5.55M |
| EPS (diluted) | $-0.76 | $-1.16 |
Analyst forecast
ForecastConsensus
none
Avg. price target
$5.00+3082.69%
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 16, 2026
- EPS actual vs est.
- $-0.12 vs —
AIDX news
All AIDX news- 20/20 BioLabs Reports Third Quarter 2026 Financial Results and Recent Business UpdatesGlobeNewswire
- REMINDER TO VOTE: 20/20 BioLabs Special Meeting of Stockholders to Be Held December 9, 2026GlobeNewswire
- 20/20 BioLabs to Host November 4 Investor Webinar on OneTest™ Commercial Expansion and Growth StrategyGlobeNewswire
20/20 Biolabs peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NEONeoGenomics Inc. | 14.82 | -1.79% | $1.92B | vs AIDX |
| ULSUL Solutions Inc. Class A | 72.64 | -2.99% | $14.67B | vs AIDX |
Indexes, lists and sector
20/20 Biolabs stock FAQ
What is 20/20 Biolabs's stock price today?
AIDX last traded at $0.1571 as of Nov 20, 4:00 PM EST, down 13.49% on the day. Prices are delayed at least 15 minutes.
Who is 20/20 Biolabs's CEO?
Mr. Jonathan Cohen is the chief executive officer of 20/20 Biolabs Inc., which has about 4 employees.
What is the AIDX 52-week high?
The 52-week high for AIDX is $50.00 and the 52-week low is $0.1556. The stock is currently 99.7% below its high.